Express Healthcare
Home  »  News  »  Breathe Well-being raises $5.5M in Series A led by Accel

Breathe Well-being raises $5.5M in Series A led by Accel

0 82
Read Article

Funds raised to be used to scale up the tech platform and team expansion

Digital Therapeutics company Breathe Well-being has raised $5.5 million in Series A led by Accel. The round saw participation from marquee investors like General Catalyst (early investors in Livongo, $20B+ US-based digital therapeutic company, Airbnb & Stripe) and Scott Shleifer, Global MD, Tiger Global. Angels have received a 30X exit and early employees have been rewarded with life changing ESOPs encashment.

The Company will invest the current fund raise to scale up the tech platform and team expansion.

Breathe’s Online Diabetes Reversal Program boasts of impressive outcomes with 95%+ patients showing HbA1c level reduction of more than 10% and 90%+ patients with completely stopped or reduced medications.

Further proving the clinical efficacy of its Digital Therapeutics Program, Breathe has successfully published a clinical study with ADA (American Diabetes Association) on more than 180 patients.

Rohan Verma, Co-founder & CEO, Breathe Well-being adds, “Our mission is to help 1 million Indians reverse Type 2 Diabetes by 2025. We are focusing on enhancing patient experience by scaling our technology platform, strengthening medical & coaching academy, community protocols and game design. This fundraise will also help us ramp up our hiring and marketing efforts. We will be aggressively hiring not only for core operations but across the board. In Accel, we have found the right kind of partnership and synergy to help us achieve our ambition of becoming the largest digital therapeutics company in the world.”

Accel India brings in 15+ years of experience helping entrepreneurs build consumer-tech companies, such as Facebook, Flipkart, BookMyShow, Myntra, Swiggy, Urban Company.

Radhika Ananth, Vice President, Accel, says, “This investment feels as much personal as professional since Rohan’s pitch struck an immediate chord as diabetes reversal is a topic close to my heart. My mom suffers from type 2 diabetes for several years and although she has been managing her condition in a disciplined way, we were unable to find a sustainable and a holistic solution to reverse it. When we met the Breathe team, it instantly dawned upon us that this was a unique opportunity, built on the premise of high efficacy, patient love and deeply engaged community. My mom is now one of their many enthusiastic customers in her journey to bring down the A1c levels to 5.6. Their execution demonstrated the best in class customer engagement and retention, something that we have never seen before in the chronic care category in India. We were able to quickly build conviction on Rohan and Aditya’s vision on creating the best product and customer experience in chronic care reversal for India and global markets.”

Aditya Kaicker, Co-founder & Chief Program Officer, Breathe Well-being, says, “We want to become the most trustworthy healthcare company in the world. The “No Outcome, No Pay” policy is a testimony to our commitment of delivering health outcomes and improving our patient’s lives. Patients are becoming more aware and excited by the possibility of Reversal through a natural lifestyle modification rather than being stuck on medications for life. Additionally, achieving full Diabetes Remission gives them more freedom in their diet and lifestyle without Diabetes-related worries.”

In the long-term, Breathe wants to extend its digital therapeutic offerings to other chronic conditions, such as hypertension, PCOS, gut disorders, etc., and establish itself as a leading global player in the market. While carrying forward its patient-first approach and continuing building the business with focus on consumer experience, trust, and clinically-proven results. Breathe Well-being raised funding from 3one4 Capital, six months back, who have also participated in this round.

Leave A Reply

Your email address will not be published.

Attend an exclusive webinar to know more about biomarkers in diagnosis & therapy management of heart failure.
Register Now
close-image
 Introducing Smart Autoinjector: Changing the paradigm of usability, cost & size
Know More?
close-image
Are you looking for ICP-MS which can increase productivity and remove time trap from your analysis?
Know More
close-image